Tea Consumption and the Risk of Colorectal Cancer in Sweden
Tea Consumption and the Risk of Colorectal Cancer in Sweden
复制标题
DOI：
10.1207/s15327914nc392_3
复制
发表时间：
2001-03
期刊：
影响因子：
--
通讯作者：
Paul Terry;A. Wolk
中科院分区：
文献类型：
--
作者：
Paul Terry;A. Wolk
饮茶与结直肠癌风险之间的关系尚不清楚。红茶的证据很少，但可能表明经常使用会增加风险。由于红茶在许多人群中是一种常见的饮料，最近报告的一个大型前瞻性芬兰男性吸烟者队列中结肠癌风险增加了两倍，这令人不安。使用考克斯比例风险模型来估计相对风险，我们在瑞典进行的一项大型、基于人群的前瞻性队列研究中检查了这种关联。在我们对61，463名女性（588，270人-年）的平均9.6年随访期间，我们观察到460例结直肠癌（291例结肠癌，159例直肠癌，10例结肠癌和直肠癌）。我们在年龄或多变量调整模型中观察到喝茶与结直肠癌之间没有关联。使用折叠暴露类别，最高暴露（≥2杯/天）与最低暴露（从不或很少）相比的多变量调整相对风险为0.97（95%置信区间= 0.63-1.48，趋势p = 0.34）。通过检查癌症亚位点的相关性，我们观察到喝茶与近端、远端或联合结肠癌之间没有相关性。然而，我们确实观察到与直肠癌的非显著正相关，在基线时≥65岁的女性中，这种正相关变得更强，具有统计学意义。我们的数据不支持芬兰研究中发现的与结肠癌的强剂量依赖性正相关。
The association between tea drinking and colorectal cancer risk remains unclear. The evidence for black tea is sparse but may indicate an increased risk with regular use. Because black tea is a common beverage in many populations, the significant twofold increased risk of colon cancer recently reported from a large prospective cohort of male Finnish smokers is disconcerting. Using Cox proportional hazards models to estimate relative risks, we examined this association in a large, population-based prospective cohort study in Sweden. During an average 9.6 years of follow-up of our cohort of 61,463 women (588,270 person-yr), we observed 460 incident cases of colorectal cancer (291 colon, 159 rectal, and 10 with both colon and rectal cancer). We observed no association between tea consumption and combined colorectal cancers in age- or multivariate-adjusted models. With the use of collapsed exposure categories, the multivariate-adjusted relative risk for the highest exposure (≥2 cups/day) compared with the lowest (never or seldom) was 0.97 (95% confidence interval = 0.63-1.48, p for trend = 0.34). Examining the association by cancer subsite, we observed no association between tea consumption and proximal, distal, or combined colon cancers. We did, however, observe a nonsignificant positive association with rectal cancers, which became stronger and statistically significant among women ≥65 years of age at baseline. Our data do not support the strong, dose-dependent positive association with colon cancer found in the Finnish study.